Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.61 |
| ▸ | KYNU | Q16719 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20272629 | 0.92 | SIRT2 (0.61) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL1162281 | 0.91 | SIRT2 (0.60) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL8386880 | 0.91 | SIRT2 (0.67) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| Hydrochloric Acid SCHEMBL1162135 | 0.90 | SIRT2 (0.59) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL21018995 | 0.88 | SIRT2 (0.62) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL12874103 | 0.87 | SIRT2 (0.65) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL12247715 | 0.87 | SIRT2 (0.65) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL1111018 | 0.87 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL1110961 | 0.87 | SIRT2 (0.60) | SIRT2SIRT1SIRT3KYNUALDH1A1 | |
| SCHEMBL15665360 | 0.87 | CTSL (0.70) | SIRT2SIRT1SIRT3KYNUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | SIRT2 2545/4885SIRT1 1483/4885SIRT3 2722/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | SIRT2 2545/4885SIRT1 1483/4885SIRT3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.